222 related articles for article (PubMed ID: 21132637)
1. [Cyclophosphamide in ANCA associated vasculitis: continuous oral vs pulse therapy].
Serpieri N
G Ital Nefrol; 2010; 27(6):566. PubMed ID: 21132637
[No Abstract] [Full Text] [Related]
2. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
Hebert LA; Rovin BH
Ann Intern Med; 2010 Jan; 152(1):64; author reply 65. PubMed ID: 20048278
[No Abstract] [Full Text] [Related]
3. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
Levine SM
Ann Intern Med; 2010 Jan; 152(1):65; author reply 65. PubMed ID: 20048281
[No Abstract] [Full Text] [Related]
4. [Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis (CYCLOPS study)].
Kötter I
Z Rheumatol; 2009 Sep; 68(7):575-7. PubMed ID: 19652987
[No Abstract] [Full Text] [Related]
5. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
Padhan P
Ann Intern Med; 2010 Jan; 152(1):64; author reply 65. PubMed ID: 20048279
[No Abstract] [Full Text] [Related]
6. Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis.
Harper L
Curr Opin Rheumatol; 2010 Jan; 22(1):37-42. PubMed ID: 19770660
[TBL] [Abstract][Full Text] [Related]
7. The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis.
Menahem S; Hiremagalur B; Mudge D; Toussaint N; Walters G;
Nephrology (Carlton); 2008 Jul; 13 Suppl 2():S24-36. PubMed ID: 18713121
[No Abstract] [Full Text] [Related]
8. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis--preliminary single center experience.
Rihová Z; Jancová E; Merta M; Zabka J; Rysavá R; Bartůnková J; Kolárova I; Tesar V
Prague Med Rep; 2004; 105(1):64-8. PubMed ID: 15354947
[TBL] [Abstract][Full Text] [Related]
9. The future of ANCA-associated vasculitis.
Holle JU; Wieczorek S; Gross WL
Rheum Dis Clin North Am; 2010 Aug; 36(3):609-21. PubMed ID: 20688253
[TBL] [Abstract][Full Text] [Related]
10. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
Harper L; Morgan MD; Walsh M; Hoglund P; Westman K; Flossmann O; Tesar V; Vanhille P; de Groot K; Luqmani R; Flores-Suarez LF; Watts R; Pusey C; Bruchfeld A; Rasmussen N; Blockmans D; Savage CO; Jayne D;
Ann Rheum Dis; 2012 Jun; 71(6):955-60. PubMed ID: 22128076
[TBL] [Abstract][Full Text] [Related]
11. Changing landscape of immunosuppression in ANCA-associated vasculitis.
Moiseev SV; Smitienko I; Bulanov N; Karovaikina E; Novikov PI
Ann Rheum Dis; 2020 May; 79(5):e59. PubMed ID: 30755415
[No Abstract] [Full Text] [Related]
12. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
de Groot K; Harper L; Jayne DR; Flores Suarez LF; Gregorini G; Gross WL; Luqmani R; Pusey CD; Rasmussen N; Sinico RA; Tesar V; Vanhille P; Westman K; Savage CO;
Ann Intern Med; 2009 May; 150(10):670-80. PubMed ID: 19451574
[TBL] [Abstract][Full Text] [Related]
13. Extracapillary glomerulonephritis type I with the coexistence of positive anti-GBM and p-ANCA antibodies.
Toledo Perdomo K; Ortega Salas R; Pérez-Sáez MJ; Esquivias de Motta E; Espinosa Hernández M; López Andreu M; López Rubio F; Aljama García P
Nefrologia; 2011; 31(1):113-5. PubMed ID: 21270926
[No Abstract] [Full Text] [Related]
14. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
Rutgers A; Kallenberg CG
Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
[TBL] [Abstract][Full Text] [Related]
15. Vasculitis: the elusive optimal induction strategy for vasculitis.
McGregor JG; Falk RJ
Nat Rev Nephrol; 2012 Feb; 8(4):195-6. PubMed ID: 22310953
[No Abstract] [Full Text] [Related]
16. An unusual presentation of C-ANCA vasculitis.
Gavrilovski M; Kakar P; Rendle J; Lawrence E; Kee K; Sathanathan R
QJM; 2012 Nov; 105(11):1105-7. PubMed ID: 21920993
[No Abstract] [Full Text] [Related]
17. [Rituximab for the treatment of ANCA associated vasculitis: the future today?].
Alba MA; Flores-Suárez LF
Reumatol Clin; 2011 Dec; 7 Suppl 3():S41-6. PubMed ID: 22115869
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis.
Almroth G; Berlin G; Andersson B; Hahn-Zoric M
Scand J Urol Nephrol; 2009; 43(2):160-70. PubMed ID: 18979374
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
20. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.
Haubitz M; Schellong S; Göbel U; Schurek HJ; Schaumann D; Koch KM; Brunkhorst R
Arthritis Rheum; 1998 Oct; 41(10):1835-44. PubMed ID: 9778225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
